Finally, n-3 PUFA can enhance eNOS activity by reducing the circulating levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of eNOS, which is increased in conditions as hypertension, renal failure, and aging [81]. The gene discussed is NOS3; the disease is acute kidney injury.